AzTrials
AzTrials

AgingChANgENCT03457870

Intermittent Energy Restriction and Chewing on Neural Stem Cell Ageing and Adult Hippocampal Neurogenesis Associated Cognition

A study testing Intermittent Energy Restriction, Chewing and Chewing + Intermittent Energy Restriction in people with Aging and Cognitive Decline, run by King's College London at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Extended bouts of periodic mastication and intermittent energy restriction (IER) may improve cognitive performance in the context of adult hippocampal neurogenesis in an ageing population. Read more about this study

Who is it for?
Ages 60 years and older, women onlyHealthy volunteers can take part
Conditions the study is for
Aging, Cognitive Decline
What is being tested?
Intermittent Energy Restriction, Chewing and Chewing + Intermittent Energy Restriction
Could I receive a placebo?
No, everyone receives an active treatment
How many people
123 participants
Where
1 siteUnited Kingdom
Study dates
18 Apr 2018to 23 Mar 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 60 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Male and female subjects.
  • 60+ years of age at the time of consent.
  • BMI 25-35.

Who cannot join

  • Subject is unable to understand the participant information sheet.
  • Subject is unable to understand and/or completely perform the cognitive testing.
  • Chews more than 3 sticks of gum per month, including nicotine replacement gum.
  • Unable to provide written informed consent.
  • Impaired vision that is not corrected.
  • Does not agree to maintain their habitual exercise routine.
Show all 22Show fewer
  • Is not in general good health on the basis of medical history.
  • Unwilling to chew gum for 3 times a day for 12 weeks.
  • Unwilling to maintain an intermittent fasting diet regime.
  • Unwilling to have blood taken.
  • History of or are currently diagnosed with a significant psychiatric disorder (e.g. schizophrenia, anxiety, PTSD).
  • Subject has any neurological disorder that could produce cognitive deterioration (e.g. Alzheimer's disease, Parkinson's disease, stroke).
  • History of traumatic brain injury, stroke or any other medical conditions causing cognitive impairment.
  • Has uncontrolled epilepsy or is prone to fainting.
  • Participated in a weight management drug trial in previous 3 months.
  • Has undergone bariatric surgery.
  • Known or suspected of alcohol abuse defined as >14 drinks per week (1 drink = 1 pint of beer, 1 large glass of wine or 50ml spirit).
  • Gastrointestinal or liver disease.
  • Subject has a sleep disorder or an occupation where sleep during the overnight hours is irregular.
  • Subjects taking the following prescription medications: Donepezil (Aricept), Galantamine (Reminyl), Rivastigmine (Exelon), Tacrine (Cognex), Bethanechol (Urecholine), Memantine (Namenda) Selegiline (Eldepryl) or any other medication for cognitive impairment.
  • Subject has a known sensitivity to the study product.
  • Individual has a condition the chief investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, might confound the interpretation of study results or put the subject at undue risk.

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Diabetes & Nutritional Sciences Division, King's College London, Franklin-Wilkins Building, 150 Stamford St

    London, England, SE1 9NH

Other trials in United Kingdom

About this study

Official title: Investigating the Impact of Intermittent Energy Restriction and Chewing on Neural Stem Cell Ageing and Adult Hippocampal Neurogenesis: The ChANgE Study

Extended bouts of periodic mastication and intermittent energy restriction (IER) may improve cognitive performance in the context of adult hippocampal neurogenesis in an ageing population. A randomised controlled parallel design trial will determine the impact of a 3 month IER diet (2 consecutive days of very low calorie diet and 5 days of normal eating) and a mastication intervention (1 piece of gum chewed for 10 minutes 3 times a day) in comparison to a control on neurogenesis-associated cognitive measures and circulating levels of the anti-ageing protein Klotho.

Read the detailed description

Nutrition and human health are strongly related. Altering overabundance through fasting/calorie-restricted diets has profound effects on homeostasis, tissue regeneration, and cancer. Tissue stem cells respond to the physiological changes that occur during fasting through dynamic shifts in their metabolism. Restricting energy intake in mice or introducing mutations in nutrient-sensing pathways can extend lifespans by as much as 50%. Post-mortems reveal that tumours, heart problems, neurodegeneration and metabolic disease are generally reduced/delayed in long-lived mice. Therefore, extending lifespan by energy restriction (ER) also seems to increase 'healthspan', the time lived without chronic age-related conditions. These insights have hardly made a dent in human medicine. Molecular and cellular insights should be established in humans to validate interventions such as ER to delay ageing and associated conditions e.g. cognitive decline (Murphy et al., 2014).

Stem cells from the central nervous system also respond to ER. Recently, the Thuret lab have found that ER, in the absence of malnutrition, promotes hippocampal stem cells to proliferate and differentiate into new-born neurons. Because these new postnatal hippocampal neurons have been shown to play a role in cognition, ER also promoted enhanced cognition in rodents (Zainuddin et al., 2012; de Lucia et al., 2017; Thuret et al., 2012). This phenomenon of neurogenesis, the process by which new neurons are generated from neural stem cells, is also occurring in humans (Spalding et al., 2013). It is a tightly regulated process occurring in the mammalian hippocampus which is an environmentally responsive brain structure known to regulate learning, memory and mood. Proposed functions of adult hippocampal neurogenesis (AHN). include enhancing recognition memory, the ability to recognise previously encountered stimuli, and pattern separation, the ability to differentially encode small changes in similar inputs (Clelland et alk., 2009; Sahay et al., 2011). It has been posited that calorie restriction may increase neurogenesis as a "cellular relic" of intermittent feeding patterns during evolution as a response to alternating periods of famine and abundant food (Murphy \& Thuret, 2015). Human trials have found significant improvements in verbal recognition memory after 30% reduction in calorie intake (Witte et al., 2009). Also, intermittent fasting in humans has been associated with significant increases in brain activation volume in areas involved in brain function control and plasticity(Belaïch et al., 2016). Food texture and mastication have also been implicated in AHN and cognitive ability (Smith et al., 2016). Decreased mastication due to the removal of molars and edentulism in both humans and animals have a negative impact on AHN and associated cognition. Human populations, in particular, have shown a close association between masticatory function, cognitive status and age-related neurodegeneration in the elderly (Miura et al., 2003). The exact mechanism by which mastication affects cognition is unknown.

Research question: In older, overweight participants does IER and/or extended periods of mastication enhance performance inhippocampus-dependent memory tasks and increase anti-ageing marker Klotho?

Objectives:

  1. A randomised controlled parallel-design trial will determine the impact of an IER diet (2 consecutive days of a very low calorie diet, 5 days of normal healthy eating for 3 months) and/or extended periods of mastication (10 minutes 3 times a day for 3 months) compared to a control group (continued habitual eating behaviour, dietary patterns) on primary outcome variables (MST and Klotho) in older, healthy participants with overweight or class I obesity.
  2. To assess the impact of an IER diet and extended periods of mastication on secondary outcomes variables including body composition, mood and sleep.
  3. To explore whether extended periods of mastication can be utilised as a weight loss/fasting aid.
Being tested
Intermittent Energy Restriction, Chewing, Chewing + Intermittent Energy Restriction
Keywords
Intermittent fasting, Adult hippocampal neurogenesis, Mastication, Pattern separation, Recognition memory, Klotho
Medical subject headings
Cognitive Dysfunction, Intermittent Fasting

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intermittent Energy RestrictionBehavioural

    Dietary advice to follow a 5:2 diet.

  • ChewingBehavioural

    Asked to chew 1 piece of gum for 10 minutes 3 times a day.

  • Chewing + Intermittent Energy RestrictionBehavioural

    Dietary advice to follow a 5:2 diet. Asked to chew 1 piece of gum for 10 minutes 3 times a day.

Study groups in NCT03457870
Study groupRoleWhat they receive
Intermittent Energy RestrictionExperimentalDietary intervention: Intermittent energy restriction
Receives: Behavioral: Intermittent Energy Restriction
ChewingExperimentalMastication intervention: chewing
Receives: Behavioral: Chewing
Chewing + Intermittent Energy RestrictionExperimentalDietary and mastication intervention: Intermittent energy restriction and chewing
Receives: Behavioral: Chewing + Intermittent Energy Restriction
ControlNo interventionNo intervention: Control

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Serum Klotho concentration

    Anti-ageing longevity protein

    Measured: Baseline

  2. Serum Klotho concentration

    Anti-ageing longevity protein

    Measured: Day 42

  3. Serum Klotho concentration

    Anti-ageing longevity protein

    Measured: Day 84

  4. Mnemonic Similarity Task

    Neurogenesis-associated cognition

    Measured: Baseline

  5. Mnemonic Similarity Task

    Neurogenesis-associated cognition

    Measured: Day 42

Secondary outcomes (66)
  1. Body weight

    Measured: Baseline

  2. Body weight

    Measured: Day 42

  3. Body weight

    Measured: Day 84

  4. Body fat percentage

    Measured: Baseline

  5. Body fat percentage

    Measured: Day 42

  6. Body fat percentage

    Measured: Day 84

  7. Body Mass Index

    Measured: Baseline

  8. Body Mass Index

    Measured: Day 42

  9. Body Mass Index

    Measured: Day 84

  10. Waist circumference

    Measured: Baseline

  11. Waist circumference

    Measured: Day 42

  12. Waist circumference

    Measured: Day 84

  13. Hip circumference

    Measured: Baseline

  14. Hip circumference

    Measured: Day 42

  15. Hip circumference

    Measured: Day 84

  16. Patient Health Questionnaire

    Questionnaire

    Measured: Baseline

  17. Patient Health Questionnaire

    Questionnaire

    Measured: Day 42

  18. Patient Health Questionnaire

    Questionnaire

    Measured: Day 84

  19. Zung Self-Rating Anxiety Scale

    Questionnaire - Scale can be scored from 20 (normal) to 80 (extreme anxiety levels). The total score is reported.

    Measured: Baseline

  20. Zung Self-Rating Anxiety Scale

    Questionnaire

    Measured: Day 42

  21. Zung Self-Rating Anxiety Scale

    Questionnaire

    Measured: Day 84

  22. Pittsburgh Sleep Quality Index

    Questionnaire

    Measured: Baseline

  23. Pittsburgh Sleep Quality Index

    Questionnaire

    Measured: Day 42

  24. Pittsburgh Sleep Quality Index

    Questionnaire

    Measured: Day 84

  25. Plasma glucose concentration

    Fasting

    Measured: Baseline

  26. Plasma glucose concentration

    Fasting

    Measured: Day 42

  27. Plasma glucose concentration

    Fasting

    Measured: Day 84

  28. Cholesterol

    Fasting

    Measured: Baseline

  29. Cholesterol

    Fasting

    Measured: Day 42

  30. Cholesterol

    Fasting

    Measured: Day 84

  31. Triglycerides

    Fasting

    Measured: Baseline

  32. Triglycerides

    Fasting

    Measured: Day 42

  33. Triglycerides

    Fasting

    Measured: Day 84

  34. High Density Lipoprotein

    Fasting

    Measured: Baseline

  35. High Density Lipoprotein

    Fasting

    Measured: Day 42

  36. High Density Lipoprotein

    Fasting

    Measured: Day 84

  37. Low Density Lipoprotein

    Fasting

    Measured: Baseline

  38. Low Density Lipoprotein

    Fasting

    Measured: Day 42

  39. Low Density Lipoprotein

    Fasting

    Measured: Day 84

  40. Total/HDL Cholesterol Ratio

    Fasting

    Measured: Baseline

  41. Total/HDL Cholesterol Ratio

    Fasting

    Measured: Day 42

  42. Total/HDL Cholesterol Ratio

    Fasting

    Measured: Day 84

  43. Plasma adiponectin concentration

    Fasting

    Measured: Baseline

  44. Plasma adiponectin concentration

    Fasting

    Measured: Day 42

  45. Plasma adiponectin concentration

    Fasting

    Measured: Day 84

  46. Plasma leptin concentration

    Fasting

    Measured: Baseline

  47. Plasma leptin concentration

    Fasting

    Measured: Day 42

  48. Plasma leptin concentration

    Fasting

    Measured: Day 84

  49. Plasma beta-hydroxybutrate concentration

    Fasting

    Measured: Baseline

  50. Plasma beta-hydroxybutrate concentration

    Fasting

    Measured: Day 42

  51. Plasma beta-hydroxybutrate concentration

    Fasting

    Measured: Day 84

  52. Plasma total cholesterol concentration

    Fasting

    Measured: Baseline

  53. Plasma total cholesterol concentration

    Fasting

    Measured: Day 42

  54. Plasma total cholesterol concentration

    Fasting

    Measured: Day 84

  55. Plasma low density lipoprotein (LDL) cholesterol concentration

    Fasting

    Measured: Baseline

  56. Plasma LDL cholesterol concentration

    Fasting

    Measured: Day 42

  57. Plasma LDL cholesterol concentration

    Fasting

    Measured: Day 84

  58. Plasma high density lipoprotein (HDL) cholesterol concentration

    Fasting

    Measured: Baseline

  59. Plasma HDL cholesterol concentration

    Fasting

    Measured: Day 42

  60. Plasma HDL cholesterol concentration

    Fasting

    Measured: Day 84

  61. Plasma triglyceride concentration

    Fasting

    Measured: Baseline

  62. Plasma triglyceride concentration

    Fasting

    Measured: Day 42

  63. Plasma triglyceride concentration

    Fasting

    Measured: Day 84

  64. Plasma total cholesterol:HDL cholesterol ratio

    Fasting

    Measured: Baseline

  65. Plasma total cholesterol:HDL cholesterol ratio

    Fasting

    Measured: Day 42

  66. Plasma total cholesterol:HDL cholesterol ratio

    Fasting

    Measured: Day 84

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Mar 2018
  2. Study start18 Apr 2018
  3. Primary completion23 Mar 2020
  4. Study completion23 Mar 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
123 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03457870
Sponsor's protocol ID
Change 2018
Acronym
ChANgE
Status last verified
Feb 2021
First submitted
23 Feb 2018
Last updated
18 Feb 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Murphy T, Dias GP, Thuret S. Effects of diet on brain plasticity in animal and human studies: mind the gap. Neural Plast. 2014;2014:563160. doi: 10.1155/2014/563160. Epub 2014 May 12.

    PubMed 24900924
  • Witte AV, Fobker M, Gellner R, Knecht S, Floel A. Caloric restriction improves memory in elderly humans. Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1255-60. doi: 10.1073/pnas.0808587106. Epub 2009 Jan 26.

    PubMed 19171901
  • Akazawa Y, Kitamura T, Fujihara Y, Yoshimura Y, Mitome M, Hasegawa T. Forced mastication increases survival of adult neural stem cells in the hippocampal dentate gyrus. Int J Mol Med. 2013 Feb;31(2):307-14. doi: 10.3892/ijmm.2012.1217. Epub 2012 Dec 18.

    PubMed 23254518
  • Smith, N., Miquel-Kergoat, S. & Thuret, S., 2016. The impact of mastication on cognition: Evidence for intervention and the role of adult hippocampal neurogenesis. Nutrition and Aging, 3(2-4), pp.115-123

Questions about this trial

What is this clinical trial studying?

A study testing Intermittent Energy Restriction, Chewing and Chewing + Intermittent Energy Restriction in people with Aging and Cognitive Decline, run by King's College London at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Serum Klotho concentration (time frame: Baseline). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03457870, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in